将128例风湿免疫系统疾病患者分为观察组与对照组,各64例.对照组给予泼尼松治疗,观察组在对照组治疗的基础上加用环磷酰胺,两组均持续4周的治疗.观察组的治疗总有效率为93.8%,对照组的治疗总有效率为84.4%,观察组比对照组明显要高,差异显著(P<0.05).两组患者的不良反应比较,差异无统计学意义(P＞0.05).观察组与对照组治疗后的关节疼痛与关节肿胀指数都明显低于治疗前(P<0.05),治疗后观察组的关节疼痛与关节肿胀指数也明显低于对照组(P<0.05).观察组治疗后的类风湿因子(RF)值为(50.22±19.82) IU·mL-1,明显低于对照组的(59.14±20.59) IU·mL-1(P<0.05),且都明显低于治疗前(P<0.05).表明观察组治疗风湿免疫系统疾病能有效调节HPA轴状况,促进RF表达下降,缓解疼痛与肿胀症状,安全性好,治疗效果更好.%A total of 128 patients with rheumatic diseases were divided into observation group and control group with 64 cases in each group. Patients in the control group were given prednisone therapy, those in the observation group received cyclophosphamide treatment based on the treatment of the control group, all patients were treated and observed for 4 weeks. The total effective rates were 93.8% and 84.4% for the observation and control groups, respectively (P＜0.05). There were no significantly different side ef-fects between the observation and control groups (P＞0.05). The values of joint pain and joint swelling in-dexes for both groups were significantly lower after treatment than before treatment (P＜0.05), and after treatment, those for the observation group were significantly lower than for the control group (P＜0.05). The rheumatic factor (RF) values after treatment were (50.22±19.82) IU·mL-1and (59.14±20.59) IU·mL-1for the observation and control groups (P＜0.05), and both were significantly lower than those before treatment (P＜0.05), respectively. So cyclophosphamide combined with prednisone for patients with rheumatic diseases can effectively regulate the HPA axis, promote the decrease of RF and relieve pain and swelling. It is safe in improving the therapeutic effects.
展开▼
